Scarica l'app Stockscreener
0.0228
33.82%
0.00575
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché GRTX Giù?
Forum
Previsione
Galera Therapeutics Inc Borsa (GRTX) Ultime notizie
Chmn Sorensen Sells 70,000 ($1.4K) Of Galera Therapeutics Inc [GRTX] - TradingView
GRTX Form 4: CEO Sorensen reports 70,000-share stock sale - Stock Titan
Chmn Sorensen Files To Sell 70,000 Of Galera Therapeutics Inc [GRTX] - TradingView — Track All Markets
Galera Therapeutics, Inc. SEC 10-Q Report - TradingView
Galera Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 - MarketScreener
[10-Q] Galera Therapeutics, Inc. Quarterly Earnings Report | GRTX SEC FilingForm 10-Q - Stock Titan
Aprea Therapeutics Reports Early Signs of Activity in APR-1051 Cancer Trial - MyChesCo
Galera Therapeutics Sells Dismutase Mimetics Portfolio to Biossil in $108.5 Million Deal - MyChesCo
Canadian company purchases Galera Therapeutics’ dismutase mimetics portfolio - Pennsylvania Business Report -
Galera Therapeutics Sells Assets to Biossil Inc. - TipRanks
Biossil to acquire Galera’s dismutase mimetics portfolio for up to $105M - MSN
Galera Therapeutics Acquires Dismutase Mimetics Portfolio by Biossil For $105 Million - citybiz
Galera Therapeutics (GRTX) Sells Asset Portfolio to Biossil - GuruFocus
Galera Therapeutics Announces Acquisition of Dismutase Mimetics Portfolio by Toronto-based Biossil for up to $105 Million - Yahoo Finance
Malvern firm selling drug portfolio in potential $105M deal after FDA setback - The Business Journals
Today's SEC FilingsLatest 10-K, 10-Q, 8-K Forms - Stock Titan
Oral Mucositis Market Size & Share | Industry Report, 2033 - Grand View Research
NanoCell Therapeutics Expands Scientific Advisory Board With Global Experts in Gene Therapy and Clinical Development - MyChesCo
Avasopasem manganese treatment for severe oral mucositis from chemoradiotherapy for locally advanced head and neck cancer: phase 3 randomized controlled trial (ROMAN) - The Lancet
Legend Biotech CorporationAmerican Depositary Shares (NQ: - FinancialContent
Galera Therapeutics Amends Royalty Agreement with Clarus - The Globe and Mail
Radiation-Induced Oral Mucositis in Head and Neck Cancer Market is expected to reach USD 1.63 billion by 2034 - openPR.com
North American Morning Briefing : Stock Futures -2- - MarketScreener
Oral Mucositis Market Growth, Trends, Consumer Demand and Key Opportunities - openPR.com
Galera Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025 - MarketScreener
Triple-Negative Breast Cancer Market Gearing Up for Impressive Growth at a CAGR of 4.7% During the Forecast Period (2025-2034) | DelveInsight - Lelezard
Windtree Therapeutics to Launch BNB Crypto Treasury Strategy in Groundbreaking $200 Million Deal - MyChesCo
Warrington’s Windtree Therapeutics Acquires Waste Management Company - BUCKSCO.Today
Lyell Immunopharma Strengthens Clinical and Commercial Capabilities with Key Board and Executive Appointments - The Manila Times
Oral Mucositis Market to Observe Stunning Growth During the Study Period (2020–2034) | DelveInsight - GlobeNewswire
Aviceda Therapeutics Appoints Ophthalmology Innovator and Industry Leader Dr. Emmett T. Cunningham, Jr. to Board of Directors - Business Wire
Galera Therapeutics Inc. (GRTX) reports earnings - qz.com
Chemotherapy Oral Mucositis Market Trends 2025-2035 - Future Market Insights
Galera Therapeutics holds annual stockholder meeting - Investing.com
Pharmacological ascorbate combined with rucosopasem selectively radio-chemo-sensitizes NSCLC via generation of H - ScienceDirect.com
Oral Mucositis Treatment Market Size to Hit USD 3.72 Billion by 2034 - Precedence Research
Malvern-based Galera Therapeutics Secures New Lease on Life with Acquirement Underway - VISTA.Today
St. Louis-born Galera Therapeutics sidesteps liquidation, acquires New York biotech company - The Business Journals
Galera Therapeutics sidesteps liquidation, acquires New York biotech company - The Business Journals
FDA Tracker: 2024 Ends With Lilly’s Landmark GLP-1 Sleep Apnea Approval - BioSpace
Twelve option delistings on December 23rd - TipRanks
Wayne’s Palvella Therapeutics Completes Reverse Merger with Pieris Pharmaceutical - VISTA Today
Radiation Induced Esophagitis Market Set to Grow Substantially Through 2032, DelveInsight Projects | Galera Therapeutics - The Globe and Mail
The 2024 Biotech Graveyard - Fierce Biotech
Oral Mucositis Market Forecasted to Surge in Coming Years, 2024-2034 Analysis by DelveInsight | Swedish Orphan Biovitrum, Galera Therapeutics, EpicentRx, Galera Therapeutics, Inc., Soligenix - Barchart.com
Galera stockholders reject liquidation plan - Investing.com
UroGen Appoints Chris Degnan as Chief Financial Officer - Yahoo Finance
Mark Bachleda takes the helm at Eyconis - BioCentury
Eyconis, Inc. Announces Appointment of Dr. Mark J. Bachleda - GlobeNewswire
Galera Therapeutics faces Nasdaq delisting - Investing.com
"Trimming the Fat or Losing the Muscle? August 2024’s Biotech Layoff Frenzy Signals Strategic 'Adjustments' in the Name of Efficiency" - BioSpectrum Asia
Galera Therapeutics set to shut down one year after devastating FDA rejection - The Business Journals
Galera Therapeutics settles lawsuit for $975,000 - Investing.com
Biopharma layoff tracker 2023: Atreca, Galera, INOVIO and more cut staff - PharmaLive
GRTX Stock Price and Chart — OTC:GRTX - TradingView — Track All Markets
Why Galera Therapeutics (GRTX) Stock Is Nosediving - TradingView
Slone Partners Places Dr. Eugene P. Kennedy as Chief Medical Officer at Carisma Therapeutics - Hunt Scanlon Media
Galera Reports First Quarter 2024 Financial Results and Recent Corporate Updates - GlobeNewswire
Galera Therapeutics Enacts Plan to Deter Hostile Takeovers - TipRanks
Galera Therapeutics Implements Stockholder Rights Plan to Shield Investor Interests - MyChesCo
0.37%
0.21%
Capitalizzazione:
|
Volume (24 ore):